The administration of recombinant chemerin ameliorate HFD-induced NASH in mice, as well as IR, leptin resistance, and liver lesions, by alleviating oxidative stress and promoting autophagy, at least in part, due to chemerin/CMKLR1-dependent activation of janus kinase 2 (JAK2)-STAT3 pathway [65]. The gene discussed is JAK2; the disease is metabolic dysfunction-associated steatohepatitis.